Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX

Kiora Pharmaceuticals — Merger or Acquisition (January 2024)

19 slides from Kiora Pharmaceuticals's merger presentation, Jan 31, 2024

  1. Slide 1: Strategic Collaboration with Théa

    Kiora Pharmaceuticals, Inc. NASDAQ: KPRX Strategic Collaboration with Théa | January 31, 2024

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements Some of the statements in this presentation are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the develo

  3. Slide 3: Sharpened Focus on Orphan Retinal Diseases

    3 Kiora is developing retinal therapeutics to improve sight in patients with severe vision loss due to inherited or age-related diseases Sharpened Focus on Orphan Retinal Diseases Patient Perspective Individual’s burden of disease Physicians Perspective Efficient, cost-effective treatments Societal

  4. Slide 4: Current Development Pipeline

    4 Current Development Pipeline Product Route of Delivery Indication Development Stage Prevalence* Pre-clinical Phase 1 Phase 2 Phase 3 (US, EU5, JP) KIO-301 Intravitreal Retinitis Pigmentosa (Mutation Agnostic) 250,000 Choroideremia 16,000 Stargardt Disease 99,000 KIO-104 Intravitreal Posterior Non-

  5. Slide 5: Théa Partnership: Co-Development & Commercialization

    5 Théa Partnership: Co-Development & Commercialization Transaction Highlights  Théa granted exclusive development & commercialization rights to KIO-301 for IRDs (≠ Asia)  $16M cash upfront payment to Kiora  Kiora eligible for up to an additional $285M in clinical development, regulatory and comme

  6. Slide 6: Kiora & Théa Partnership: Strategic Rationale

    6 Kiora & Théa Partnership: Strategic Rationale Near-term Resources to Fund all KIO-301 Clinical Development  Anticipated Phase 2 trial expenses to be fully reimbursed  TOI to conduct Phase 3 trials Financial Flexibility  Ability to fund KIO-104 clinical development in Posterior Non-Infectious Uv

  7. Slide 7: Who is Théa?

    7  Private, family owned, ophthalmic focused company  Chibret family founded the French Society of Ophthalmology in 1883  >100 commercial ophthalmic products globally including: Azasite® Cosopt® Ivizia® Virgan® Zioptan® Other partnerships include: Théa products available in over 75 countries dire

  8. Slide 8: KIO-301 Small Molecule Targeting Vision Restoration

    8 KIO-301 Small Molecule Targeting Vision Restoration Inherited Retinal Diseases

  9. Slide 9: Inherited Retinal Diseases Lead to Loss of Vision

    9 Inherited Retinal Diseases Lead to Loss of Vision Healthy Vision  Rods and cones, the photoreceptors of the retina, process light and relay an electrical signal to downstream cells.  One of these cell types, retinal ganglion cells (RGCs), transmit the signal to the visual cortex.  The visual co

  10. Slide 10: KIO-301 is a Molecular Photoswitch Designed to Restore Vision

    10 KIO-301 is a Molecular Photoswitch Designed to Restore Vision KIO-301 without Light  When photoreceptors die, RGCs undergo some remodeling, including expressing specific proteins that allow KIO-301 to selectively enter the cell with ion channels.  Without light, KIO-301 remains in its linear “o

  11. Slide 11: Retinitis Pigmentosa: A Disease with No Available Treatments

    11 Clinical Presentation  Night blindness, reduced visual field range and eventual loss of central vision  Visual acuity declines  50% of patients are not qualified to drive by age 37 and legally blind by 55 Etiology  50+ genetically distinct subtypes from 150+ mutations  Inherited disease Mark

  12. Slide 12: ABACUS-1 Takeaways

    12 ABACUS-1 Takeaways Patients report improvements in vision  Consistent with objective clinical assessments  Follow-on study will include sham group Pilot study limitations  Non-controlled  Small sample size Approvable outcome assessments discussed with regulators  Positive US FDA pIND meeting

  13. Slide 13: KIO-301-2101: Phase 2 Study Design (ABACUS-2)

    13 KIO-301-2101: Phase 2 Study Design (ABACUS-2) Randomized (3:1), Controlled*, Double Masked, Multiple Dose Study – 4 Sites (Australia)  Primary: Safety & Tolerability ᵯ� AEs, vitals ECG, chemistry and hematology, SD-OCT, FAF, slit lamp, IOP  Secondary: Efficacy (change from baseline @ 11 weeks)

  14. Slide 14: KIO-104 Intravitreal Small Molecule DHODH Inhibitor

    14 KIO-104 Intravitreal Small Molecule DHODH Inhibitor Steroid Sparing Approach to Retinal Inflammation

  15. Slide 15: KIO-104 Overview (DHODH Inhibitor)

    15 KIO-104 is an intravitreal, non-steroidal, novel small molecule which mitigates:  Metabolic activity and proliferation of T-cells  Secretion of IL-17, VEGF and IFN-ᵯ� KIO-104 Overview (DHODH Inhibitor) Existing immunosuppressive agents have a fundamentally different mode of action on T-cells co

  16. Slide 16: Non-Infectious Uveitis

    16 Non-Infectious Uveitis Br J of Ophthalmol. 2004;88(9):1159-1162. Med Hypothesis Discov Innov Ophthalmol. 2013 Winter;2(4):113-120. Retina Today. 2016;47-51. Clin Ophthalmol. 2016;10:1983-2020. JAMA Ophthalmol. 2016 Nov 1;134(11):1237-1245. Uveitis Market Insights, Epidemiology & Market Forecast-2

  17. Slide 17: KIO-104 Path Forward

    17 KIO-104 Path Forward Posterior Non-Infectious Uveitis • Ph2b Clinical Trial (EU): Q4 2024 – Q1 2026 • Non-Clinical, IND Enabling Studies: Q1 2025 – Q1 2026 • Ph3 Registration Study(s) in USA & EU: Q3 2026 – Q1 2028 • NDA: Late 2028 Proliferative Vitreoretinopathy and/or other retinal inflammatory

  18. Slide 18: Upcoming Clinical/Regulatory Milestones

    18 Q4 ‘23 Q1 ‘24 Q2 ‘24 Q3 ‘24 Q4 ‘24 KIO-301 ABACUS-1 ✓ Top Line Data KIO-301 ABACUS-2 Ph2 Initiation KIO-301 ABACUS-2 Ph2 Top Line Data* KIO-301 Initiated Choroideremia ‘Extension’ KIO-301 Stargardt Ph2 Initiation KIO-301 ✓ FDA pIND RP KIO-301 EMA Meeting IRDs KIO-301 ODD Choroideremia KIO-301 ODD

  19. Slide 19: Highlights

    19 Highlights KIO-301 Strategic Partnership  Théa reimburses clinical development through Phase 2  Théa conducts Phase 3  Significant achievable milestone payments  Long-term upside from Théa commercial capabilities, milestones and royalties Pipeline Opportunities  KIO-301 Asia licensing  KIO-

Kiora Pharmaceuticals — Merger or Acquisition (January 2024) on 6ix